Skip to main content
NOVT logo

NOVT · Novanta Inc · Documents

Track NOVT — free
$117.89 +2.56 (+2.22%) At close · Nov 18 Q1 2026 earnings call transcript
Market Cap
$4.46B
Shares
37.82M
Volume · Nov 18 456.34K Avg daily vol (3M) 441.37K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $980.6M up 3.3% 10-K filed Feb 23, 2026 Quarterly report FY2026 Q3 Revenue $305.01M up 23.1% 10-Q filed Nov 9, 2026 Latest results Revenue and Adjusted EBITDA rise, full-year outlook maintained 8-K filed Nov 9, 2026 Earnings call Q1 2026 earnings call Held May 12, 2026
2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Oct 2
Revenue rises 23.1% as Riverpoint Medical acquisition weighs on operating income

Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.

Revenue $305.01M ▲ 23.1% Net income $2.02M ▼ 81.1% Diluted EPS $0.05 ▼ 83.3%
Read from the MD&A section
3 source passages
Total revenue of $305.0 million for the three months ended October 2, 2026 increased $57.2 million, or 23.1%, from the prior year period primarily due to revenue from the 2026 acquisition and a 16.0% increase in revenue in the Automation Enabling Technologies segment and 3.5% increase in the Medical Solutions segment excluding the impact of our 2026 acquisition. Operating income of $13.9 million for the three months ended October 2, 2026 decreased $7.9 million, or 36.3%, from the prior year period. This decrease was attributable to an increase in restructuring, acquisition, and related costs of $16.4 million, an increase in amortization expense of $7.8 million, an increase in selling, general, and administrative expenses of $6.2 million, and an increase in research and development, and engineering expenses of $2.3 million, partially offset by an increase in gross profit of $24.7 million. On July 23, 2026, we completed the acquisition of all outstanding equity interests of the parent company of Riverpoint Medical for total upfront cash consideration of $1,200.6 million, net of cash acquired, subject to customary closing and net working capital adjustments. In addition, the agreement provides for a milestone payment of $250.0 million payable on or before January 8, 2027. Open the document at this passage
Nov 9
Current report 8-K
Revenue and Adjusted EBITDA rise, full-year outlook maintained

Novanta reported third-quarter GAAP revenue of $305 million, up 23%, while Adjusted EBITDA rose 38% to $80 million. It expects full-year 2026 GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.

Financial results
3 source passages
- Third Quarter 2026 GAAP Revenue increased 23% to $305 million - Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million For the full year 2026, the Company now expects GAAP revenue to be in the range of $1,135 million to $1,140 million, reflecting reported growth of approximately 16%. The company expects Adjusted EBITDA to be in the range of $274 million to $277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per diluted share, or 11% to 13% growth. Open the document at this passage
Oct 2
Current report 8-K/A Events of Jul 22
Current report

Novanta Inc. completed its acquisition of Runway Buyer, LLC on July 23, 2026 for approximately $1.2 billion in cash, plus a $250.0 million milestone payment due on or before January 8, 2027. Runway Buyer reported 2025 revenue of $136,120,000 and net income of 11,462,563.

Read from the first part of this long document
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jul 3
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $265.81M ▲ 10.3% Net income $12.54M ▲ 178.9% Diluted EPS $0.30 ▲ 150.0%
May 11
Quarterly report 10-Q FY2026 Q1, ended Apr 3
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $257.71M ▲ 10.4% Net income $21.1M ▼ 0.5% Diluted EPS $0.51 ▼ 13.6%
Apr 24
Proxy statement DEF 14A Meeting May 28, 2026
Proxy statement AI summary on its way
Feb 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $980.6M ▲ 3.3% Net income $53.83M ▼ 16.0% Diluted EPS $1.47 ▼ 16.9%
2025
Nov 3
Quarterly report 10-Q FY2025 Q3, ended Sep 26
Quarterly report for FY2025 Q3
Revenue $247.84M ▲ 1.4% Net income $10.65M ▼ 44.5% Diluted EPS $0.30 ▼ 43.4%
Aug 5
Quarterly report 10-Q FY2025 Q2, ended Jun 27
Quarterly report for FY2025 Q2
Revenue $241.05M ▲ 2.2% Net income $4.5M ▼ 67.3% Diluted EPS $0.12 ▼ 68.4%
May 6
Quarterly report 10-Q FY2025 Q1, ended Mar 28
Quarterly report for FY2025 Q1
Revenue $233.37M ▲ 1.1% Net income $21.21M ▲ 44.5% Diluted EPS $0.59 ▲ 43.9%
Feb 25
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $949.25M ▲ 7.7% Net income $64.09M ▼ 12.1% Diluted EPS $1.77 ▼ 12.4%
2024
Nov 5
Quarterly report 10-Q FY2024 Q3, ended Sep 27
Quarterly report for FY2024 Q3
Revenue $244.41M ▲ 10.3% Net income $19.19M ▼ 9.6% Diluted EPS $0.53 ▼ 10.2%
Showing 1–50 of 144 documents
Key facts CIK 1076930 CUSIP 67000B104 13F (30d) 387 filings 356 filers Visit website Investor relations